A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Clinical trial NCT02621021 · RECRUITING
Trial details
- NCT number
- NCT02621021
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-04
- Primary completion
- 2028-06-16
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.